Azodi M, Chambers S K, Rutherford T J, Kohorn E I, Schwartz P E, Chambers J T
Division of Gynecologic Oncology, Yale University School of Medicine, New Haven, Connecticut 06520-8063, USA.
Gynecol Oncol. 1999 Jun;73(3):348-53. doi: 10.1006/gyno.1999.5395.
The aim of this study was to review the management and outcome of patients with adenocarcinoma in situ of the cervix and to evaluate the significance of endocervical cone margin status in these patients.
A retrospective review of records between January 1988 and December 1996 identified 40 patients with adenocarcinoma in situ on cone biopsy for whom complete information was available. The median follow-up was 38 months.
The mean age was 37 years, and the mean parity was 1.3. Fifty-three percent of the patients had prior abnormal cervical cytology. The initial Pap smear that led to the patient's referral was abnormal in 39 (98%). Initial cervical biopsies showed adenocarcinoma in situ and/or glandular dysplasia in 28 (70%), squamous dysplasia in 2 (5%), chronic inflammation in 2 (5%), and no pathologic changes in 2 (5%) patients. Initially no biopsies were performed in 3 (7.5%) patients and the results of 3 (7.5%) biopsies were unknown. Subsequently, all patients had cone biopsies. The endocervical margins were positive for glandular abnormalities in 24% of cold knife cones (CKC), 75% of LEEPs, and 57% of laser cones. The ectocervical margins were positive for squamous and/or glandular abnormalities in 8% of CKCs, 13% of LEEPs, and 57% of laser cones. ECCs above the cone were obtained in 28 patients, and only 1 (3%) was positive. The definitive treatment was hysterectomy in 27, repeat cone in 5, and no additional therapy in 8 patients. The pathology showed residual disease in 44% of treated patients. From 16 cone biopsies with negative margins who had subsequent treatment, there was residual disease in 5 (31%) specimens (1 adenocarcinoma in situ, 1 mild glandular dysplasia, 3 glandular atypia). From 16 cones with positive margins who had subsequent treatment, there was residual disease in 9 (56%) specimens. The patients with negative ECCs above the cone regardless of margin status had residual disease in 58% of treated specimens.
Women with adenocarcinoma in situ of the uterine cervix had residual disease in 31% of cases with negative margins in cone biopsies and/or with negative ECCs and in 56% of cases with positive endocervical margins. LEEP cones had higher rate of positive endocervical margins (75%) compared to CKC (24%) and laser cone (57%). If maintaining reproductive capacity is desired, we would recommend CKC; however, this does not guarantee absence of the disease.
本研究旨在回顾宫颈原位腺癌患者的治疗及预后情况,并评估这些患者宫颈管锥切边缘状态的意义。
对1988年1月至1996年12月期间的记录进行回顾性分析,确定40例行锥切活检确诊为原位腺癌且资料完整的患者。中位随访时间为38个月。
患者平均年龄37岁,平均产次1.3。53%的患者既往有宫颈细胞学异常。导致患者前来就诊的初始巴氏涂片异常的有39例(98%)。初始宫颈活检显示原位腺癌和/或腺体发育异常的有28例(70%),鳞状上皮发育异常2例(5%),慢性炎症2例(5%),2例(5%)患者无病理改变。最初3例(7.5%)患者未行活检,3例(7.5%)活检结果未知。随后,所有患者均行锥切活检。宫颈管切缘腺体异常阳性率在冷刀锥切(CKC)中为24%,环形电切术(LEEP)中为75%,激光锥切中为57%。宫颈外口切缘鳞状和/或腺体异常阳性率在CKC中为8%,LEEP中为13%,激光锥切中为57%。28例患者获取了锥切上方的宫颈管内膜刮除术(ECC)标本,仅1例(3%)为阳性。最终治疗方案为子宫切除术27例,再次锥切5例,8例患者未接受额外治疗。病理显示44%接受治疗的患者有残留病灶。在后续接受治疗的16例切缘阴性的锥切活检标本中,5例(31%)有残留病灶(1例原位腺癌,1例轻度腺体发育异常,3例腺体异型增生)。在后续接受治疗的16例切缘阳性的锥切标本中,9例(56%)有残留病灶。无论切缘状态如何,锥切上方ECC阴性的患者中58%的治疗标本有残留病灶。
宫颈原位腺癌患者中,锥切活检切缘阴性和/或ECC阴性的病例中有31%存在残留病灶,宫颈管切缘阳性的病例中有56%存在残留病灶。与CKC(24%)和激光锥切(57%)相比,LEEP锥切的宫颈管切缘阳性率更高(75%)。如果希望保留生育能力,我们推荐CKC;然而,这并不能保证无疾病残留。